The round was led by Asset Management Ventures, with participation from all existing investors, and joined by Bertelsmann. This new investment will accelerate the growth of SubjectWell's existing clinical trial patient recruitment efforts, expand its support of cancer research, and fund production of its awareness initiatives for post-approval treatments.

SubjectWell, the audience engagement platform for healthcare, is raising awareness of clinical research in the general population - providing patients more choice and easy access to innovative treatment options.